Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetRevenue - OtherRevenue - RentalShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Maxcyte (MXCT) Cost of Revenue (2020 - 2026)

Maxcyte has reported Cost of Revenue over the past 6 years, most recently at -$9.2 million for Q4 2025.

  • Quarterly Cost of Revenue fell 242.1% to -$9.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, down 87.02% year-over-year, with the annual reading at $6.2 million for FY2025, 76.66% down from the prior year.
  • Cost of Revenue was -$9.2 million for Q4 2025 at Maxcyte, down from $3.9 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $23.8 million in Q4 2023 and troughed at -$9.2 million in Q4 2025.
  • The 5-year median for Cost of Revenue is $3.1 million (2021), against an average of $3.2 million.
  • Year-over-year, Cost of Revenue plummeted 299.98% in 2022 and then soared 682.72% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $4.1 million in 2021, then plummeted by 299.98% to -$8.2 million in 2022, then surged by 391.1% to $23.8 million in 2023, then plummeted by 72.81% to $6.5 million in 2024, then crashed by 242.1% to -$9.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Cost of Revenue are -$9.2 million (Q4 2025), $3.9 million (Q3 2025), and $5.8 million (Q2 2025).